Mereo BioPharma Group - Public Comps and Valuation Multiples

Mereo BioPharma Group Overview

About Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Founded

2015

HQ

Employees

Website

mereobiopharma.com

Sectors

Biopharmaceuticals

Financials

LTM Revenue $18.9M

LTM EBITDA -$21.9M

EV

$239M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Mereo BioPharma Group Financials

As of August 2025, Mereo BioPharma Group reported last 12-month revenue of $18.9M and EBITDA of -$21.9M.

In the same period, Mereo BioPharma Group generated $18.6M in LTM gross profit and -$31.6M in net income.

See Mereo BioPharma Group valuation multiples based on analyst estimates

Mereo BioPharma Group P&L

In the most recent fiscal year, Mereo BioPharma Group reported EBITDA of -$40.8M.

Mereo BioPharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Mereo BioPharma Group valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$18.9M	XXX	n/a	XXX	XXX	XXX
Gross Profit	$18.6M	XXX	n/a	XXX	XXX	XXX
Gross Margin	98%	XXX	n/a	XXX	XXX	XXX
EBITDA	-$21.9M	XXX	-$40.8M	XXX	XXX	XXX
EBITDA Margin	-116%	XXX	n/a	XXX	XXX	XXX
EBIT	-$28.2M	XXX	-$45.7M	XXX	XXX	XXX
EBIT Margin	-149%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$31.6M	XXX	-$43.3M	XXX	XXX	XXX
Net Margin	-167%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Mereo BioPharma Group including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $18.9M. EBITDA for the last twelve months was -$21.9M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$18.9M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$18.6M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	98.4% gross margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$21.9M	Analyst estimates available to subscribers	-$40.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-115.9% EBITDA margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$28.2M	Analyst estimates available to subscribers	-$45.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-149.0% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$31.6M	Analyst estimates available to subscribers	-$43.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-167.3% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Mereo BioPharma Group

This financial data table provides comprehensive performance metrics for Mereo BioPharma Group, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Mereo BioPharma Group generated $18.9M in revenue over the last twelve months.
The company achieved -$21.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $18.6M.
Net income over the last twelve months reached -$31.6M.

Fiscal Year Performance

Fiscal year EBITDA was -$40.8M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Mereo BioPharma Group. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Mereo BioPharma Group Stock Performance

Mereo BioPharma Group has current market cap of $294M, and EV of $239M.

Market Cap Evolution

Mereo BioPharma Group Stock Data

As of September 12, 2025, Mereo BioPharma Group's stock price is $2.

See Mereo BioPharma Group trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$239M	$294M	XXX	XXX	XXX	XXX	$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Mereo BioPharma Group Valuation Multiples

Mereo BioPharma Group's trades at 23.9x EV/Revenue multiple, and -5.9x EV/EBITDA.

See valuation multiples for Mereo BioPharma Group and 15K+ public comps

Mereo BioPharma Group Financial Valuation Multiples

As of September 12, 2025, Mereo BioPharma Group has market cap of $294M and EV of $239M.

Equity research analysts estimate Mereo BioPharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Mereo BioPharma Group has a P/E ratio of -9.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$294M	XXX	$294M	XXX	XXX	XXX
EV (current)	$239M	XXX	$239M	XXX	XXX	XXX
EV/Revenue	12.6x	XXX	23.9x	XXX	XXX	XXX
EV/EBITDA	-10.9x	XXX	-5.9x	XXX	XXX	XXX
EV/EBIT	-8.5x	XXX	-5.2x	XXX	XXX	XXX
EV/Gross Profit	12.8x	XXX	n/a	XXX	XXX	XXX
P/E	-9.3x	XXX	-6.8x	XXX	XXX	XXX
EV/FCF	3.7x	XXX	-7.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mereo BioPharma Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Mereo BioPharma Group Margins & Growth Rates

Mereo BioPharma Group's last 12 month revenue growth is 89%

Mereo BioPharma Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.

Mereo BioPharma Group's rule of 40 is -171% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mereo BioPharma Group's rule of X is 108% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Mereo BioPharma Group and other 15K+ public comps

Mereo BioPharma Group Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	89%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-116%	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	-113%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-171%	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	108%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial